GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.

Aging & Longevity, Alzheimer's Research Corey Hubbafd Aging & Longevity, Alzheimer's Research Corey Hubbafd

Beyond the Plaque Trap: How Spinal Cord Drugs, Immune Sleep Fixes, and Smart Injections Are Transforming Global Alzheimer’s Care in 2026

Discover the first-week November 2026 Alzheimer's research breakthroughs. Learn how repurposed spinal cord drugs repair DNA, immune cells restore sleep, 5-year CTAD trial data proves longevity, and smart home healthtech supports caregivers.

Read More
FDA, NIH, Biotech & Drug Discovery, AI/ML Corey Hubbafd FDA, NIH, Biotech & Drug Discovery, AI/ML Corey Hubbafd

The Frontier of Innovation: Cleveland Clinic and the Application of Large Language Models in Drug Discovery

The Cleveland Clinic, a renowned leader in medical innovation, is at the forefront of this revolution, pioneering the use of LLMs to address critical challenges in drug discovery. This essay will explore the innovative approaches being pursued by the Cleveland Clinic in this domain, examining the potential impact of LLMs on the future of medicine.

Read More

Battling Alzheimer's: A New Hope on the Horizon

Alzheimer's Disease. The very name evokes a sense of dread, a long, slow fading of memory, personality, and ultimately, life itself. It's a condition that not only devastates those who suffer from it but also places an immense emotional and physical burden on their families and caregivers. For years, the scientific and medical communities have been locked in a relentless battle against this formidable foe, striving to understand its origins, slow its progression, and ideally, find a cure.

Read More

A Simple Blood Test Revolutionizes Alzheimer's Care: Why Roche's FDA Greenlight Changes Everything

The landscape of Alzheimer’s disease diagnosis and treatment is on the cusp of a dramatic transformation, thanks to the recent US Food and Drug Administration (FDA) clearance of a novel blood-based test developed by Roche. This approval is not just another step in medical technology; it signifies a potential "care paradigm shift" by introducing a simple, accessible tool that can efficiently evaluate the risk of Alzheimer’s disease pathology, particularly in primary care settings.

Read More

The Blood Test "Smoke Detector": How AI Helps Family Doctors Spot Alzheimer’s Early

For decades, the path to an Alzheimer’s diagnosis has been a marathon, not a sprint. Patients and families often face months of uncertainty, navigating a complex web of specialist referrals, expensive PET scans, and invasive spinal taps. This delay is particularly challenging in primary care, where family doctors

Read More

A New Era in Alzheimer's Research: Moving Beyond Amyloid

For decades, the public conversation surrounding Alzheimer’s disease focused almost exclusively on a single culprit: sticky protein deposits in the brain known as amyloid-beta plaques. The dominant theory held that if medicine could simply scrub these plaques away, memory loss and cognitive decline could be halted.

Read More
Clinical Operations, FDA Compliance, NIH Corey Hubbafd Clinical Operations, FDA Compliance, NIH Corey Hubbafd

The Alzheimer’s Revolution: Simple Blood Tests Spotting Risk Years Before Symptoms

For decades, Alzheimer’s disease has been a silent and elusive adversary. It crawls slowly through the brain, dismantling neural connections and building up toxic protein barriers long before the first lapse in memory occurs. Traditionally, confirming a diagnosis of Alzheimer’s has been a reactive process. Patients and their families had to wait for undeniable symptoms—confusion, forgetfulness, and changes in behavior—before seeking medical confirmation. By the time these symptoms manifest, significant and often irreversible brain damage has already occurred.

Read More

Estrogen Receptor ERβ: A New Hope in the Fight Against Alzheimer’s in Women

If you look at the statistics for Alzheimer’s disease, one striking detail immediately stands out: almost two-thirds of all people living with Alzheimer's are women. For decades, scientists and doctors explained this gap simply by pointing to the calendar—women

Read More

"Lonely Waves" and Genetic Timers: The Latest Alzheimer’s Breakthroughs Decoded

If you opened Google Scholar or picked up the latest issues of Nature Neuroscience or The Lancet Neurology over the past few days, you would spot two huge themes: how our sleep architecture betrays early brain changes, and how combining blood tests with genetics creates an exact clock for when symptoms will start.

Read More

Eliminating Bias in Pre-Screening: How Agentic AI Parses Unstructured EHR Notes for Alzheimer’s Research

Discover how Glassbury AI’s agentic architecture and zero-text FHIR mapping help biopharma sponsors achieve FDA Diversity Action Plan (DAP) compliance and eliminate Alzheimer’s trial screen failures.

Read More